| Ytd | -1.19% | |
| 1y | 20.52% |
| Open | 7.64 | Prev Close | 7.57 | Low | 7.28 | High | 7.70 | Mkt Cap | 492.91M |
| Vol | 1.05M | Avg Vol | 575.10K | EPS | -1.02 | P/E | N/A | Forward P/E | N/A |
| Beta | 1.23 | Short Ratio | 27.74 | Inst. Own | 12.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 7.45 | 200-d Avg | 7.36 | 1yr Est | 0.00 |
EPRX News
VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupra
HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Wedbush analyst Martin Fan initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a O
Gainers Gelteq (NASDAQ:GELS) stock moved upwards by 20.3% to $0.84 during Wednesday's after-mar
U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the
Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a
US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $39
Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, COD
Top analysts changed outlook on top names. See all rating changes at benzinga.com/analyst-stock-rati
Stifel analyst Annabel Samimy initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which missed t
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX)
HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX)
HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX)
This is the first release of 36-week symptom response & tissue health data for the highest dose
William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market poten
Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85,
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX)
HC Wainwright & Co. analyst Brandon Folkes maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) w
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.37) per share which missed t
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX)
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market
Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares rose sharply during today’s pre-market